Recipharm AB. (4/11/22). "Press Release: Recipharm Completes US Biologics Acquisitions".

	Region	Massachusetts (federal state)
	Country	United States (USA)
	Organisation	Arranta Bio (US)
	Group	Recipharm (Group)
	Organisation 2	Vibalogics GmbH
	Group	Recipharm (Group)
	Product	contract manufacturing (biologicals)
	Product 2	advanced therapeutic product (gene therapy, cell therapy, tissue engineering products)
	Index term	Ampersand–Recipharm: investment, 202202–202204 acquisition of Arranta Bio by Recipharm AB
	Index term 2	Ampersand–Recipharm: investment, 202202–202204 acquisition of Vibalogics by Recipharm AB
	Person	Funk, Marc (Recipharm 202301 Board Director before since 202103 CEO before 200901–202001 Lonza)
	Person 2	Stevens, David (Recipharm 202204– CEO of Arranta Bio before COO)

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.

The acquisitions reflect Recipharm’s strategy of building its presence in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs (advanced therapy medicinal products). They follow Recipharm’s entry into biologics earlier this year with the acquisition of Portuguese company GenIbet.

The acquisitions also enable Recipharm to establish a robust base in the US, with facilities in Boxborough, MA, and provide a platform from which to build its capabilities in new biologics modalities.

Both CDMOs have established specialisms within the biologics space. Boxborough-based Arranta Bio has emerged as a leader in delivering microbiome therapeutic products and mRNA clinical production capabilities. Vibalogics holds a prominent position in the manufacture of oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, manufacturing, testing and fill-finish services from facilities in Cuxhaven, Germany as well as Boxborough, MA.

As Arranta Bio moves into the next phase of its growth, it is also being announced that Mark Bamforth will be stepping down as CEO; his role will be taken by David Stevens, currently the company’s President and COO.

Marc Funk, CEO of Recipharm, said: “This acquisition is an important step in growing our Biologics business and developing our US presence. We will be building on the pioneering excellence which lies at the heart of these companies and providing drug developers in the Biologics market with scientifically differentiated CDMO services and expertise for ATMPs.

These deals, together with our recent acquisition of GenIbet, a specialist in the manufacture of biological clinical material, mean that we will be well placed to develop new capabilities in innovative technologies across gene therapy, viral vectors, mRNA/ plasmids, oncolytic virus and microbiome.

I would also like to take this opportunity to congratulate Mark on his achievements in building the Arranta Bio operation so successfully. I am looking forward to working with both David as he takes over the leadership at Arranta Bio and with Tom Hochuli at Vibalogics as we move into the next exciting phase of our combined growth.

We are thrilled to be closing both acquisitions and look forward to welcoming the Arranta Bio and Vibalogics teams into the Recipharm organisation.”

Contact information:

Marcus Smith, Head of Communications at Recipharm, marcus.smith@recipharm.com

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm and our services, please visit www.recipharm.com

About Arranta Bio

Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team of about 170, state-of-the-art facilities, and unparalleled resources are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across multiple sites with technology platforms designed to meet the evolving demands of our clients and partners.

Additional information about Arranta Bio is available at www.arrantabio.com

About Vibalogics

Vibalogics is a specialized global Contract Development and Manufacturing Organization (CDMO) offering process and analytical development, manufacturing, testing and fill-finish services to innovators developing transformational virotherapy products. From its headquarters and commercial facility in Boxborough, MA, USA and operations in Cuxhaven, Germany, Vibalogics supports its customers in the development and commercialization of oncolytic viruses, viral vectors for gene therapy and viral vaccines.

Additional information about Vibalogics is available at www.vibalogics.com
Recipharm completes US biologics acquisitions

Recipharm AB (publ)

Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com

Record changed: 2023-06-05